Staar Surgical downgraded to Neutral from Buy at BTIG

BTIG downgraded Staar Surgical (STAA) to Neutral from Buy with no price target While the firm expected Staar to reset its long-term guidance for a slower China as macro conditions have continued to worsen, it is “surprising” that Staar”s FY25 guidance is for $275M at the midpoint based on the assumption that China will materially reaccelerate despite little clarity as to what supports this reacceleration, the analyst tells investors. The firm feels it best to move to the sidelines until it has more conviction on a recovery in China and see clearer indications of management’s ability to set expectations.